Filing Flows › Azenta (AZTA) › Q2 FY26 › vs Q2 FY25
Azenta (AZTA) Q2 FY26 vs Q2 FY25 (year over year)
Azenta's revenue rose $1.5M (+1%) from $143M in Q2 FY25 to $145M in Q2 FY26. The biggest changes: Sample Management Solutions +$1.3M (+2%); Multiomics +$182K (+0.3%).
Azenta, Q2 FY26: revenue $145M (+1% year over year), operating margin -114.5%, net loss $161M, operating cash flow $13.5M. The chart draws each line against Q2 FY25, the increases inside each band.
Margins
| Q2 FY26 | Q2 FY25 | Change | |
|---|---|---|---|
| Free cash flow margin | 4.2% | 4.9% | -0.7 pts |
Every line
| Line | Q2 FY26 | Q2 FY25 | Change | % |
|---|---|---|---|---|
| Core Products | $44.3M | $47.9M | −$3.6M | -7% |
| Sample Repository Services | $36.8M | $31.9M | $4.9M | +15% |
| Sample Management Solutions | $81.1M | $79.8M | $1.3M | +2% |
| Multiomics | $63.7M | $63.5M | $182K | +0.3% |
| Revenue | $145M | $143M | $1.5M | +1% |
| Other income, net | $4.7M | −$22.2M | $26.9M | — |
| Income tax benefit | $323K | −$7.2M | $7.6M | — |
| Net loss | $161M | $47.7M | $113M | +237% |
| Costs & expenses | $311M | $191M | $120M | +63% |
| Operating costs | $311M | $162M | $149M | +92% |
| Cost of revenue | $82.8M | $80.6M | $2.2M | +3% |
| Research & development | $9.4M | $7.6M | $1.8M | +24% |
| SG&A | $67.9M | $69.8M | −$1.9M | -3% |
| Other operating costs | $151M | $3.6M | $147M | 42× |
| Operating cash sources | $174M | $62.1M | $112M | +181% |
| Depreciation & amortization | $14.0M | $14.0M | $49K | +0.4% |
| Share-based compensation | $6.4M | $8.3M | −$2.0M | -24% |
| Working capital & other | $154M | $39.8M | $114M | +287% |
| Net loss absorbed | $161M | $47.7M | $113M | +237% |
| Operating cash flow | $13.5M | $14.4M | −$890K | -6% |
| Free cash flow (OCF − capex) | $6.1M | $7.0M | −$885K | -13% |
| Capital expenditures | $7.4M | $7.4M | −$5K | -0.1% |
Questions
How much did Azenta's revenue grow year over year in Q2 FY26?
Azenta's revenue rose $1.5M (+1%) from $143M in Q2 FY25 to $145M in Q2 FY26.
What drove Azenta's revenue change in Q2 FY26?
Sample Management Solutions +$1.3M (+2%); Multiomics +$182K (+0.3%).